Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803-827

doi:10.1016/S0873-2159(15)30156-2

Article information

Download PDF

Statistics

Full text is only aviable in PDF

Bibliografia/Bibliography

[1.]

A. Araújo, et al.

Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células.

Rev Port Pneumol, 14 (2008), pp. 803-827

Medline

[2.]

National Comprehensive Cancer Network.

Practice Guidelines in Oncology – v.2.2009 Non-Small Cell Lung Cancer.

http://www.nccn.org/professional/physician_gls/f_guidelines.asp

[3.]

National Institute for Health and Clinical Excellence.

Updated guide to the methods of technology appraisal.

(June 2008)http://nice.org.uk/media/B52/A7/TAMethodsGuideUpsdatedJune2008.pdf

[4.]

F.A. Shepherd, J. Pereira, T. Ciuleanu, et al.

Erlotinib in previously treated non-small cell lung cancer.

N Engl J Med, 353 (2005), pp. 123-132

http://dx.doi.org/10.1056/NEJMoa050753 | Medline

[5.]

F.A. Shepherd, et al.

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based therapy.

J Clin Oncol, 18 (2000), pp. 2095

http://dx.doi.org/10.1200/jco.2000.18.10.2095 | Medline

[6.]

N. Hanna, F.A. Shepherd, F.V. Fossela, et al.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

J Clin Oncol, 22 (2004), pp. 1589-1597

http://dx.doi.org/10.1200/JCO.2004.08.163 | Medline

[7.]

W. Kotowa, U. Gatzemeier, O. Pirk, et al.

A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.

Journal of Medical Economics, 10 (2007), pp. 255-271

[8.]

National Institute for Health and Clinical Excellence.

Pemetrexed for the treatment of non-small-cell lung cancer.

(August 2007)http://www.nice.org.uk/TA124

[9.]

M.A. Socinski, D.E. Morris, G.A. Masters, R. Lilenbaum.

Chemotherapeutic management of stage IV non-small cell lung cancer.

Chest, 123 (2003), pp. 226-243

[10.]

C. Gridelli, P. Maione, A. Rossi, et al.

New avenues for second-line treatment of metastatic non-small-cell lung cancer.

Expert Rev Anticancer Ther, 9 (2009), pp. 115-124

http://dx.doi.org/10.1586/14737140.9.1.115 | Medline

[11.]

T.E. Stinchcombe, M.A. Socinski.

Considerations for second-line therapy of non-small cell lung cancer.

On-cologist, 13 (2008), pp. 28-36

[12.]

J. Carlson, N. Oestreicher, D.P. Lubeck, et al.

Cost-effectiveness of erlotinib vs docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology, 25 (2007), pp. 425

[13.]

C. Chouaid, A. Vergnenegre, A. Moser, et al.

Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer: a French observational study.

Value in Health, 10 (2007), pp. A322

[14.]

S. Capri, A. Morabito, G. Carillio, et al.

Economic evaluation of erlotinib, docetaxel and pemetrexed as second line treatment in patients with advanced non-small-cell lung cancer (NSCLC): A cost-minimization in Italian hospitals.

Value in Health, 10 (2007), pp. A333

[15.]

S. Stefani, M.G. Saggia, E.A. Santos.

Cost-minimization analysis of erlotinib versus docetaxel or pemetrexed as second-line therapy for non-small-cell lung cancer (NSCLC) from the perspective of a private payer in Brazil.

Value in Health, 10 (2007), pp. A332k

[16.]

T.C. Hsia, G.C. Chang, Y.M. Chen, et al.

Cost-effectiveness analysis of erlotinib compared with docetaxel and pemetrexed for second-line treatment of advanced non-small cell lung cancer (NSCLC) in Taiwan.

Value in Health, 10 (2007), pp. A325

[17.]

O. Batigun, E. Yildrim.

Pharmacoeconomic analysis of erlotinib compared with docetaxel for the treatment of relapsed non-small-cell lung cancer (NSCLC) in Turkey. PCN77.

Value in Health, 10 (2007), pp. A234

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter